A Phase 2 Study of BA3011 Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Non-small Cell Lung Cancer (nsclc)
-
Age: Between 18 Year(s) - 100 Year(s)
-
Gender: Male or Female
-
Other Inclusion Criteria:
1) Patients must have prior disease progression on a PD-1/L-1 inhibitor (either monotherapy or in combination with another therapy such as ipilimumab) and have histologically or cytologically confirmed locally advanced unresectable or metastatic NSCLC 2) Patients with EGFR or anaplastic lymphoma kinase (ALK) genomic tumor aberrations should have had disease progression on FDA-approved therapy for these aberrations. 3) Patients must have a life expectancy of at least 3 months.
You may not be eligible for this study if the following are true:
-
1) Patients must not have clinically significant cardiac disease, in the judgment of the Investigator. 2) Patients must not have known congestive heart failure (New York Heart Association classes II-IV) or serious cardiac arrhythmia requiring treatment. 3) Patients with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment are excluded. 4) Patients with severe renal impairment (creatinine clearance [CrCL] less than 30 mL/min) are excluded.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
